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Objectives: Biliary mucinous cystic neoplasms (BMCNs) are recently redefined rare liver tumours in
which insufficient recognition frequently leads to an incorrect initial or delayed diagnosis. A concise review
of the subtle, sometimes non-specific, clinical, serologic and radiographic features will allow for a
heightened awareness and more comprehensive understanding of these entities.
Methods: Literature relating to the presentation, diagnosis, treatment, pathology and outcomes of
BMCNs and published prior to March 2012 was reviewed.
Results: Biliary mucinous cystic neoplasms most commonly occur in females (60%) in the fifth decade
of life. Clinical symptoms, serologic markers and imaging modalities are unreliable for diagnosis of
BMCNs, which leads to misdiagnosis in 55–100% of patients. Perioperative cyst aspiration is not
recommended as invasive BMCNs can only be differentiated from non-invasive BMCNs by microscopic
evaluation for the presence of ovarian-type stroma. Intraoperative biopsy and frozen section(s) are
essential to differentiate BMCNs from other cystic liver lesions. The treatment of choice is complete
excision and can result in excellent survival with initial correct diagnosis.
Conclusions: A low threshold for considering BMCN in the differential diagnosis of cystic liver lesions
and increased attentiveness to its subtle diagnostic characteristics are imperative. The complete surgical
resection of BMCNs and the use of appropriate nomenclature are necessary to improve outcomes and
accurately define prognosis.
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Introduction
Biliary mucinous cystic neoplasms (BMCNs) of the liver are rare
entities. Previously, these lesions have been reported under the
general terms of ‘biliary cystadenoma’ and ‘biliary cystadenocar-
cinoma’. This trend continues to pervade the literature. However,
this lesion type was redefined and classified by the World Health
Organization (WHO) in 2010 and is now defined as ‘a cyst-
forming epithelial neoplasm, usually with no communication
with the bile ducts, composed of cuboidal to columnar, variably
mucin-producing epithelium, associated with ovarian-type sub-
epithelial stroma’ and is subdivided into non-invasive and invasive
types.1 Non-invasive mucinous cystic neoplasms (MCNs) are cat-
egorized by the highest degree of cytoarchitectural atypia present
into three groups: (i) MCNs with low-grade intraepithelial dys-
plasia; (ii) MCNs with intermediate-grade intraepithelial dyspla-
sia, and (iii) MCNs with high-grade intraepithelial dysplasia.1 If
there is an invasive carcinoma component, the lesion is denoted as
an MCN with associated invasive carcinoma.1 Based on the
current requirement for the presence of ovarian-type stroma, it is
likely that many of these neoplasms previously reported as vari-
ants without ovarian stroma would now be classified as intraduc-
tal papillary neoplasms (IPNs) of the bile ducts with marked cystic
changes.1
Invasive BMCNs, along with their slightly more common coun-
terparts, non-invasive BMCNs, arise from the liver, bile duct and,
occasionally, gallbladder2 and together are routinely reported to
comprise <5% of all liver cysts.3–8 Some authors believe this is an
overestimation and assert that BMCNs probably account for <1%
of liver cysts.9,10 It has been proposed that BMCNs may represent
5% of all symptomatic hepatic cysts referred for therapy.9,10
As a result of equivocal clinical findings and challenging pre-
operative radiologic assessment, intrahepatic invasive BMCN is
often difficult to distinguish from non-invasive BMCN, hepatic
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abscess, cholangiocarcinoma and other benign liver cysts.2,8,11
Insufficient recognition as a result of this tumour’s low incidence
can delay correct diagnosis to the point at which curative man-
agement is no longer possible.13,14
The treatment of choice for both non-invasive and invasive
BMCN is surgical excision, but resectability is dependent on the
anatomic location of the tumour, functional liver reserve and
medical comorbidities.2,7,8,15–17 Complete surgical resection is criti-
cal in order to reliably identify the tumour’s degree of malig-
nancy.2,4 Reported recurrence rates following complete surgical
excision vary between 10% and 13%, but can be affected by study
sizes that are frequently small as a result of the rarity of these
tumours.2,18,19 Unlike other primary hepatic tumours, systemic
therapies have not been found to be particularly effective in the
treatment of primary invasive BMCN.
A review of the presentation, diagnosis, treatment, pathology
and outcomes of BMCNs is presented.
Materials and methods
Searches of MEDLINE and EMBASE were performed to identify
case reports, case series and articles pertaining to diagnostic
imaging and pathology of MCNs of the liver published prior to
March 2012. The search terms included ‘mucinous cystic neo-
plasm’, ‘biliary cystadenoma’ and ‘biliary cystadenocarcinoma’.
Additional articles were obtained by cross-referencing relevant
articles. An organized discussion regarding the presentation,
diagnosis, pathology, treatment and outcomes of MCNs of the
liver was then undertaken. The article selection process is summa-
rized in Fig. 1. The Cochrane Database of Systematic Reviews was
then cross-checked to confirm that no similar reviews had been
undertaken.
Results
Epidemiology and clinical presentation
Intrahepatic non-invasive and invasive BMCNs comprise <5% of
all liver cysts.7,8,20 The invasive BMCN (then referred to as a ‘biliary
cystadenocarcinoma’) was first described by Willis in 1943 and
defined as an entity by Edmondson in 1958 as a multilocular
lesion lined by columnar epithelium with an accompanying
densely cellular (‘ovarian-like’) stroma.11,12,17 Over the 70 years
since its definition, its exact incidence among malignant hepatic
epithelial tumours has remained unknown, but has been reported
to be as low as 0.41%.7,13,20–22 This may actually be an underesti-
mation as both non-invasive and invasive BMCNs are being
discovered with increasing frequency secondary to advances in
abdominal imaging and as a result of growing awareness of the
cysts themselves.10,15,23,24 Of note, the incidence of simple hepatic
cysts has been established by both computed tomography (CT)
and autopsies to be 14–24% and to increase with age.20,23
Primary intrahepatic BMCN most commonly presents in the
fifth decade of life, occurs more commonly in females (approxi-
Potentially relevant publications
identified and screened for retrieval
n = 471 Publications excluded n = 292
209 = multiple hits
83 = non-English language
publications
Publications excluded n = 67
67 = not relevant
Publications retrieved for more detailed
evaluation
n = 143
Potentially appropriate publications to
be included in review (including
references)
n = 83
Publications included in review by
article type
Case series/reports = 50
Pathology = 13
Diagnostic imaging = 18
Meta-analysis = 1
Editorial = 1
Figure 1 QUORUM (quality of reporting of meta-analyses) algorithm of review of biliary mucinous cystic neoplasms
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mately 60%) and appears to occur at even higher rates in women
if there is no associated invasive carcinoma.1,11,17,19,24 Clinical mani-
festations are non-specific and widely variable. Frequent com-
plaints (in approximately 60% of patients) include right upper
quadrant or epigastric pain or discomfort, abdominal fullness
and a palpable abdominal mass.2,8,15,25,26 Less frequent symptoms
include fever, weight loss, jaundice and ascites.2,8 Elevated liver
function tests are reported in up to 26% of patients.2 However, it
is not uncommon for a patient to be asymptomatic at presenta-
tion (30–58%).4,11,27–29 Diagnostic imaging of BMCNs is difficult
and can frequently lead to missed or delayed diagnosis.15,16,19
Ultrasound (US), CT and magnetic resonance imaging (MRI) all
typically demonstrate non-specific multilocular tumours with
septal or mural nodules.2
In a thought-provoking case series by Zhang et al., the inciden-
tal finding of invasive BMCN after laparoscopic resection for
hepatic cystic lesions is discussed.19 These authors made presump-
tive diagnoses by US of hepatic cysts in two patients and cystad-
enomas in three patients.19 All five patients were found to have
invasive BMCNs on final pathology, which again emphasizes that
invasive BMCNs cannot be reliably diagnosed or distinguished
from other liver cysts using preoperative imaging alone.
Differential diagnosis
The critical issue in the workup of a complicated cystic lesion of
the liver concerns the distinguishing of primary intrahepatic non-
invasive and invasive BMCNs from benign conditions that require
only conservative management and observation.30 In addition to
primary non-invasive and invasive BMCNs, differential diagnosis
should include hepatic abscess, haematoma, haemorrhagic cyst,
simple congenital cyst, hydatid (echinococcal) cyst, polycystic
disease, cystic hamartoma or post-traumatic cysts, Caroli’s
disease, other neoplastic lesions such as undifferentiated embryo-
nal sarcoma, cystic primary hepatocellular carcinoma, metastatic
pancreatic or ovarian cystadenocarcinoma, intraductal papillary
mucinous neoplasm biliary type (IPMN-B) and hepatobiliary
mesenchymal tumours (particularly biliary smooth muscle neo-
plasms), such as biliary leiomyoma, adenomyoma and primary
hepatic leiomyosarcoma (Table 1).4,13,20,24,25,31,32
Given the extensive possibilities in differential diagnosis of a
complicated cystic hepatic lesion, liver abscess and hydatid cyst
are the two entities reported to be the most likely to be confused
with non-invasive and invasive BMCNs.31,33 That the incidence of
simple hepatic cysts increases with age further complicates the
problem as patients with unilocular non-invasive or invasive
BMCN are subject to an increased likelihood of misdiagnosis.10
Metastatic lesions with cystic degeneration and cystic cholangio-
carcinoma, as well as primary or metastatic necrotic neoplasms,
should also be considered.4,13,20,24,25,31,32
Recently, Wang et al. sought to develop an algorithm for the
preoperative differentiation of non-invasive and invasive BMCNs
in their retrospective review of 20 non-invasive and 30 invasive
BMCNs.28 Overall, older age, male gender and shorter symptom
duration were associated with a higher possibility of invasive
BMCN.28 Arterial blood flow and nodule enhancement tended to
be more common in invasive BMCN, but this increase in fre-
quency did not reach statistical significance.28 Additional patients
are needed to validate this scoring system, but it may be of poten-
tial clinical value in the future.
Rare presentations
Recurrent jaundice with cholangitis has been reported as a rare
presentation. For example, a patient reported by Ishak et al. had
three episodes of obstructive jaundice over a 19-month period.8
Initially, the patient underwent excision of a completely occluding
common bile duct tumour, but suffered two subsequent recur-
rences of invasive BMCN.8
Compression of the portal system and inferior vena cava
obstruction have also been reported as rare presentations. One
such patient, with multiple hepatic tumours but without reported
presenting symptoms, was found to have compression of the right
main portal vein and hepatofugal flow in the left gastric vein on a
post-arterial portogram.7 The patient was reported to have no
evidence of disease at 7 months after resection of invasive
BMCN.7 Others have reported bilateral lower extremity swelling
as a result of vena cava obstruction.8,34 Subclinical fevers have been
noted as occasional initial presentations of invasive BMCN.20
Infrequently, presentations with painful haemorrhage, tumour
rupture or fever from secondary infection have been described.34,35
Pathophysiology
Biliary mucinous cystic neoplasms are slow-growing, frequently
reach a large size, and can progress over a period of years to
invasive carcinoma.1 There are several different theories regarding
the origin of intrahepatic BMCNs. One of the most predominant
theories is malignant epithelial transformation from non-invasive
to invasive BMCN, which is believed to occur over a period of
several years.8,11,19 In 1970, this transformation was demonstrated
in rats fed on an aflatoxin diet.36 The potential for malignant
transformation from non-invasive to invasive BMCN has also
been documented retrospectively on review of serial CT imaging
in a few individuals.15,37–39 This type of invasive BMCN is noted to
have a characteristic mesenchymal stroma and a much higher
predilection for females, and to follow a relatively indolent course
in most patients.2,40
The presence of ovarian stroma in BMCNs suggests a correla-
tion with ovarian MCNs and has led to the hypothesis of an
embryonal origin.6 It has been suggested that the close proximity
of the liver and gonads during embryonic development is respon-
sible for the migration of gonadal cells into the liver surface and
the resultant ovarian stroma in these lesions.6,41 Further, the peri-
toneal surface epithelium of the embryonic gonads has been
found to be lined with bulging cells as opposed to the typical
flattened celomic epithelium. The examination of embryos sug-
gests that during the embryonic period, these bulging cells detach
and migrate into the surfaces of nearby organs such as the liver.6
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Biliary mucinous cystic neoplasms may arise from neoplasia of
the normal intrahepatic bile ducts, as a result of malignant trans-
formation of other cystic lesions in the liver or from congenital
hepatic or biliary malformations.2,11,19,42–44 These congenital mal-
formations or anomalies may include choledochal cysts, Caroli’s
disease, congenital hepatic fibrosis, polycystic disease and ectopic
remnants of primitive foregut sequestered in the liver.2,8,42,43 The
majority of these tumours are slow-growing.2
All types of BMCN can become quite large; they range from
1.2 cm to 40 cm in size28,29,31,45 and are found to be multilocular in
up to 84% of patients.2,46 Both non-invasive and invasive BMCNs
occur in both the right and left lobes. Some authors have reported
that all BMCNs (non-invasive and invasive types) demonstrate a
predilection for the right hepatic lobe,5,8,31,34,47 whereas others
report a predilection for the left hepatic lobe in non-invasive
and/or invasive BMCNs.3,4,15,27,48 Yet other studies have revealed no
lobe-specific predilection.21,33,40 The most recent analysis of the
clinical characteristics of non-invasive and invasive BMCNs, by
Wang et al., found that 70% of tumours were located in the left
lobe of the liver (n = 21).28 All invasive BMCNs were noted to
affect the left lobe (10/10, 100%), whereas all those in other lobes
were benign.28
Invasive BMCN can be differentiated from non-invasive BMCN
only by microscopic examination.7,13 Based on experience, frozen-
section microscopy can confirm or deny the presence of a BMCN
on a consistent basis as it requires only evaluation for the presence
or absence of mucinous epithelium and ovarian-type stroma.
Thus, it is essential to perform a cyst wall biopsy using frozen
sections at the time of operation. Invasive BMCN is more difficult
to diagnose as stromal invasion is challenging to identify and may
at times be present in only very focal areas (Fig. 2). Therefore,
resected cysts should be extensively sampled before a final patho-
logical diagnosis is rendered.
Morphologically, invasive BMCN differs from non-invasive
BMCN in that cellular pleomorphism, anaplasia and infiltration
of the underlying fibrous stroma are present in invasive BMCN,
but absent from non-invasive BMCN.8,14,49 The lining cells of the
cyst show considerable variation in size and atypia in their nuclei,
as well as loss of polarity.8,49 More simply, although extensive
infiltration of mucin-producing adenocarcinoma can be found in
the walls of the cyst, there can also be occasional patches of lining
that are benign and consist of a single layer of cuboid to columnar
epithelium.8,50 In the variant in which mesenchymal (‘ovarian-
like’) stroma is present, it is visualized between an inner epithelial
lining and an outer connective tissue capsule.15,51 Figure 3 (a–c)
shows illustrative examples. Papillary projections of the epithelial
cells are also common.50
Invasive BMCN is noted to be strongly reactive for cytokeratins
7, 8, 18 and 19, and epithelial membrane antigen (EMA).1,2,52 Focal
expression of carcinoembryonic antigen (CEA) can also be seen.1
In a light microscopic and immunohistochemical study of 70
patients with non-invasive and invasive BMCNs, conducted by
Devaney et al., immunohistochemistry did not yield a diagnostic
immunoprofile with which to distinguish non-invasive BMCN
from invasive BMCN or from other epithelial lesions arising
within the abdominal cavity.21
When present, associated invasive carcinoma is usually limited
to the primary neoplasm.1 However, in some circumstances the
invasive carcinoma may spread to the liver parenchyma or metas-
tasize to regional hepatoduodenal ligament lymph nodes.1 Staging
follows the protocol of the tumour–node–metastasis (TNM) clas-
sification for intrahepatic cholangiocarcinoma.1
It should be noted that the histologic features of intrahepatic
BMCNs parallel those of their pancreatic, ovarian and retroperi-
toneal counterparts. Notably, all these tumours lack communica-
tion with the duct system and contain mucin-producing
epithelium.41 Zamboni et al. studied the clinicopathologic features
of 56 patients with MCNs of the pancreas and determined that the
similarities (i.e. gender, morphology, stromal lutenization)
between all four types of MCN suggested a common developmen-
tal pathway.41 In comparison with MCNs of the pancreas, intra-
hepatic BMCNs more commonly have cuboidal, non-mucinous
epithelium.1
Intraductal papillary mucinous neoplasm biliary type (some-
times previously referred to as ‘intraductal biliary papilloma’) is
one of the more recent tumours added to the differential diagnosis
of an MCN in the liver. In 2005, Aoki et al. described a patient with
an IPMN-B that was morphologically similar to non-invasive
BMCN.53 A preoperative diagnosis of biliary cystadenoma (non-
invasive BMCN) was made based on preoperative imaging and
resection was performed. On pathologic review, a single layer of
normal columnar epithelium and a papillary tumour were found
to be growing from the wall of the dilated bile duct,53 but two
distinct differences were apparent. Firstly, the interstitium was
normal and neither smooth muscle cells nor ovarian-like stroma
were detected.53 Secondly, extramural tumour infiltration was not
Figure 2 Histopathology showing glands with cribriform architec-
ture infiltrating stroma. (Haematoxylin and eosin stain; original
magnification ¥40)
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observed and in tumour cells, mucus staining of d-periodic acid
Schiff was strongly positive, but immunostaining for CEA and
carbohydrate antigen 19-9 (CA 19-9) were negative.53 As with
most rare tumours, a definitive diagnosis is usually only made
postoperatively. A ‘biliary cystadenoma without ovarian stroma’,
as reported in a series of patients by Wheeler and Edmondson,11
may actually be an IPMN-B.53
In earlier classifications, variations of biliary cystadenocarci-
noma were described without mesenchymal stroma. These cur-
rently would be considered IPMN-Bs, as previously discussed.1,53
It is still important that the differential diagnosis should consider
these aggressive lesions, which are not felt to arise from biliary
cystadenomas and which are noted to occur more frequently in
males (male : female ratio: 2 : 1).2,11,54 When this type does occur
in females, it typically presents 30 years earlier than the more
indolent form, which also indicates a different point of origin.11
It is imperative to remember that, as previously indicated with
reference to the differential diagnosis, a liver abscess can mimic a
non-invasive BMCN and even when there is clinical suspicion,
aspiration may not yield a correct diagnosis, especially in the
chronic phase. Yamamoto et al. reported a patient with a cystic
liver lesion in whom negative cytology and cultures grossly
appeared to indicate a solid lesion, but whose final diagnosis indi-
cated a chronic liver abscess.55 This also further emphasizes that
gross features alone are not sufficiently reliable to enable the
definitive diagnosis of a BMCN.
Diagnosis
Laboratory findings
Although there are no specific markers or characteristics that can
consistently identify intrahepatic BMCNs, standard liver cancer
markers should be considered to rule out other similarly present-
ing tumours (see Table 1). Liver function tests are generally
normal, but elevated levels of bilirubin, alkaline phosphatase and
gamma-glutamyl transpeptidase (GGT) have been seen in cases
in which intra- or extrahepatic biliary duct compression are
present.4,56,57 CA 19-9 may be elevated (particularly if there is an
associated invasive carcinoma), but CEA and alpha-fetoprotein
(AFP) are usually normal.19,58
Additionally, especially in individuals living in endemic regions
or with appropriate travel histories, testing for echinococcal cysts
should be carried out (most frequently by serologic tests; eosino-
philia may also be present if there is cyst leakage).24,59 Although
indirect haemagglutination is a better screening test, the current
reference standard is the immunoglobulin G (IgG) enzyme-linked
immunosorbent assay (ELISA), which detects IgG antibodies
to hydatid cyst fluid-derived native or recombinant antigen B
subunits.58–60 However, 10–20% of patients do not produce detect-
able serum antibodies (IgG), resulting in false negatives.59 Less
frequently used, the indirect immunofluorescence assay (IFA) is
the most sensitive test (95%), but sensitivity and specificity largely
depend on the quality of the utilized antigen.60,61 The sensitivity
and specificity of the ELISA are also highly dependent on the
Figure 3 Histopathology showing (a) the cyst lining with papillary
projections into the cyst lumen and ovarian-type stroma (arrow) and
(b) high-grade dysplasia/carcinoma in situ overlying spindle cell/
ovarian stroma. [Haematoxylin and eosin stain; original magnifica-
tion (a) ¥10, (b) ¥40.] (c) Immunostain for oestrogen receptor
highlighting ovarian-type stroma. (Original magnification ¥40)
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antigen preparation method, cross-reactions with other helmin-
thic diseases and non-infectious conditions.59,61 The specificity of
the ELISA using hydatid cyst fluid is often unsatisfactory, but high
levels of sensitivity (95%) and specificity (100%) can be achieved
with pure antibody.58,59,61
A preoperative biopsy is contraindicated in view of the risk for
spillage, which may result in the possible seeding of the perito-
neum and the subsequent development of peritoneal carcinoma-
tosis, pseudomyxoma or pleural dissemination.2,20,25,32,49,50
Aspiration cytology has been found to have a sensitivity of 66% in
distinguishing neoplastic from non-neoplastic liver cysts.16,62,63
Elevated CEA and CA 19-9 levels in the cyst fluid of both BMCNs
and simple hepatic cysts have been reported. Koffron et al. com-
pared levels of CEA and CA 19-9 in the cyst fluid of 22 patients
with non-invasive BMCNs, four patients with simple cysts and
four patients with polycystic liver disease.64 Markedly increased
levels of CA 19-9 and mild to marked increases in CEA levels were
found in all of the patients with non-invasive BMCNs, whereas no
elevated values were found in the eight control patients.64
However, three other studies evaluating the significance of
cystic fluid analysis in the differential diagnosis of BMCN found
no statistically significant differences in CA 19-9 or CEA levels
among patients with, respectively, non-invasive BMCNs, invasive
BMCNs and simple cysts.27,29,65
After resection, cyst content analysis can be useful. The content
is most frequently viscous and yellowish in colour.66 Dark red and
blood-stained aspirate is a commonly described variant and
debate continues about its significance and possible prognostic
implications, but in general it is considered concerning for malig-
nancy.17,67 Buetow et al. examined the correlation between find-
ings in clinical imaging and pathology results in 27 non-invasive
and seven invasive BMCNs, and also evaluated the importance of
ovarian stroma.40 A statistically significant correlation was found
between non-bilious fluid and the presence of ovarian stroma, but
did not indicate whether the tumour was an invasive or a non-
invasive BMCN.40
Imaging
Diagnostic imaging of intrahepatic MCNs is difficult and can
frequently lead to misdiagnosis.15,16,19,32,40 (See Table 1 for US, CT
and MRI findings in various cystic lesions of the liver.) Intrahe-
patic BMCNs are easily mistaken for simple cysts, hydatid cysts or
Caroli’s disease.41 In hepatic cysts with intracystic haemorrhage, it
may be difficult to distinguish the cyst from a cystic neoplasm.47 It
has been reported that correct diagnoses are made in <50% of
cases, even when all three imaging modalities are utilized.15,16,68
This claim is supported by reports of previous studies in which
prior interventions (e.g. percutaneous drainage, marsupialization,
partial resection, internal drainage, sclerosis) were performed as a
result of misdiagnosis before eventual resection and appropriate
diagnosis in 42–55% of cases and in 100% in one series.9,10,15,33,34
Abdominal US often reveals a well-demarcated, mostly mul-
tilocular hypoechogenic mass, which sometimes shows character-
istic papillary projections from the cyst wall and septae.1,2,69 Type
III hydatid cysts (daughter cysts and/or matrix formation with
calcifications) can be differentiated from non-invasive and inva-
sive BMCNs on the basis of oval or round daughter cysts demon-
strated on US.70 Computed tomography scanning demonstrates a
hypodense cystic lesion consistently in most patients (Fig. 4a, b),
but internal papillary projections and intrahepatic bile duct dila-
tation are both seen in fewer than half of cases.2,15
The presence of a mural nodule was significantly more frequent
in BMCNs on multivariate analysis of biliary cystic tumours
(non-invasive and invasive BMCNs) and in simple cysts mimick-
ing non-invasive BMCN in US and CT scans.27 In a subset com-
parison of non-invasive and invasive BMCNs, a mural nodule,
Figure 4 (a) Selected arterial-phase cross-sectional computed tomography images of biliary cystadenocarcinoma. (b) Venous-phase coronal
reconstructions demonstrating a patent venous inflow and outflow of segments VI and VII
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calcification, bile duct dilation and intracystic debris were all char-
acteristic of invasive BMCNs.27 Further, several authors have
stated that mural nodularity may be strongly indicative of malig-
nancy.5,9,27,33,40,48 Internal septations have been found to be more
suggestive of BMCNs (both benign and malignant) than simple
cysts in recent series.15,28,29,47 Septations and septal thickening are
also significantly more likely to be associated with non-invasive
BMCN.29 Calcifications can be seen in both non-invasive and
invasive BMCNs and coarse calcifications have been reported to
increase the likelihood of invasive BMCN in some studies.29,33,40
With specific reference to a direct comparison between US and
CT, one study reported that CT showed decreased sensitivity in
demonstrating internal septae (eight of 10 multilocular lesions) in
comparison with US (five of five lesions).33 Further CT findings
included thick and coarse mural and septal calcifications in two of
three invasive BMCNs and mural soft-tissue nodules in the lone
case of a unilocular invasive BMCN.33 Ultrasound and CT have
been noted to be mutually complementary in the evaluation of
BMCNs.33,45
Findings in US or CT of one or more of the following char-
acteristics should be considered highly suspicious for invasive
BMCN: multilocular hypodense mass with echogenic internal
septations and papillary projections into the cystic space; coarse
and thick cyst wall; presence of haemorrhage or necrosis in the
cyst; cyst wall enhancement with contrast, and fine septal
calcifications in the cyst wall (usually more frequent on CT
scan).14–16,19,27
Magnetic resonance imaging of intrahepatic BMCNs may be
ordered secondary to the presence of suggestive findings on US or
CT scan or it may be the primary imaging method utilized.30,31,63
Intracystic haemorrhage and corresponding low signal intensity
on T2 weighted images may suggest malignancy, although, to date,
no direct correlation has been found.16
The use of positron emission tomography-CT (PET-CT) with
fluorine-18-2-fluro-2-deoxy-D-glucose (FDG) has been reported
in only a single case series of four patients with invasive BMCN, all
of whom demonstrated intense FDG uptake.71 The authors con-
cluded that it is possible that PET-CT may routinely contribute to
the diagnosis of malignant cystic tumours in the liver in the
future.71 Two additional reports have described PET scans only
and both reported findings positive for malignancy.9,72
Thus, imaging itself cannot completely and reliably differenti-
ate between non-invasive BMCN, invasive BMCN and other
hepatic cystic neoplasms, but it is valuable for localizing the lesion
and operative planning.19,46,48,63 In the absence of reliable radio-
logic criteria, diagnosis is often revealed only after the surgical
specimen is examined.
Treatment
It is clear that the incomplete excision of primary intrahepatic
BMCNs leads to recurrence and thus the mainstay of treatment is
complete surgical resection of these tumours.15–17,26,50,51,73 Descrip-
tions of previous experiences with techniques such as aspiration,
fenestration, internal drainage, intratumoral sclerosant applica-
tion and incomplete resection report recurrence rates of
90–100%.25,66,74 Complete resection is important because it is pos-
sible to find the synchronous appearance of non-invasive BMCN
and the foci of carcinoma in situ, and the latter may be undetected
at the borders of the cyst.4,49
In addition to open surgery, laparoscopic surgery for both
benign and indeterminate liver lesions including BMCNs has been
found to be safe, incurring morbidity rates of 7–10% and no
mortality, and to achieve oncologic efficiency.64,75,76 Rates of
conversion from laparoscopic to open procedures are low
(0–8%).64,75,76 Of two studies that reported follow-up, one study
identified no recurrences at a mean of 16 months (range:
4–54 months)64 and the other reported one recurrence at a mean
of 55 months (range: 3–115 months).75 Careful patient and
tumour selection are imperative to the successful laparoscopic
management of BMCNs.64,75,76 There are anecdotal reports of
patients with BMCNs managed by orthotopic liver transplant
(OLT).77,78 The benign nature and slow growth rate of BMCNs, as
well as the ongoing shortage of donor livers, will allow for OLT in
only very select patients who are not amenable to other forms of
radical surgical therapy.77
Meta-analysis and case series
In 1998, Lauffer et al. reported a meta-analysis of 112 patients
with invasive BMCNs already reported in the literature.2 Patients
who underwent hepatic lobectomy (n = 24) were found to have 2-
and 5-year survival of 65%.2 All of the patients who underwent
complete excision of the lesion (n = 16) were alive at 5 years, but
two patients had required a second operation for recurrence.2 A
2-year survival rate of 68% was achieved in patients who under-
went left or right hemihepatectomy (n = 11) and one patient
required an operation for recurrence.2 The partial excision of
these tumours (n = 9) yielded survival of 71% at 2 years, but only
36% at 5 years.2 It also led to a 67% recurrence rate in comparison
with recurrence rates of 15% and 13% after anatomic resection (n
= 6) and complete excision (n = 16), respectively.2 Segmentectomy
(n = 6) was reported to yield a 2-year survival rate of 100%, but
50% of patients required reoperation for recurrence.2 The authors
of this analysis noted that it was not possible to determine whether
the procedures of hepatic lobectomy, hemihepatectomy or seg-
mentectomy resulted in complete or incomplete tumour exci-
sion.2 No data on postoperative complications were given.
Since this initial meta-analysis, five recent case series including
a total of 89 patients with non-invasive (n = 63) or invasive (n =
26) BMCNs have been published (Table 2).4,6,10,15,72 The average
age of these patients was 52 years and 72% (n = 64) were female.
In the two series in which gender and age were reported by BMCN
subgroup, 88% of patients with non-invasive BMCNs (n = 22) and
39% of patients with invasive BMCNs (n = 7) were female.4,72
Patients with non-invasive BMCNs were noted to be almost
15 years older than those with invasive BMCNs. Right upper
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quadrant pain was the most common symptom in all BMCNs,
regardless of subgroup, occurring in 55% of patients (n = 49).
Three of the studies reported laboratory findings (n = 52).4,10,72
Levels of CA 19-9 were elevated in 16 patients, 13 of whom had
non-invasive BMCNs. Only one study (n = 9) reported cyst fluid
tumour markers (aspirations were performed only in non-
invasive BMCNs); seven patients were found to have elevated
CA 19-9 and four were found to have elevated CEA in their cyst
fluid.10 The most common imaging modality was CT scan, but US
and/or MRI were also used in all four of the studies that reported
imaging results.4,6,15,72 The most prominent findings included mul-
tiseptated cysts, sometimes with solid components and thickened
irregular walls, as well as internal septations. Previous interven-
tions had been performed in 28% of patients (n = 25) and were
widely variable (see Table 2). Two studies did not report on pre-
vious interventions.4,6
Surgery was carried out in 94% of patients (n = 84).4,6,10,15,72
Resection was the most common operation and was carried out in
74% of the patients who underwent surgical procedures (n = 62).
Enucleation was performed in 16 patients (19%), partial excision
in five patients (6%) and cyst fenestration in one patient. Three of
the five studies reported complications, resulting in an average
complication rate of 17.6% (range: 9.7–30.0%).4,6,72 One periop-
erative death was reported, but did not appear to be related to the
procedure performed.72
One study6 did not report longterm follow-up; two studies4,10
reported only combined follow-up data for all patients, and two
studies15,72 provided follow-up data for the non-invasive and inva-
sive BMCN subgroups, respectively. The latter two studies
included 37 patients with non-invasive BMCN, of whom 31
underwent complete resection; 30 patients remained alive with no
evidence of disease (NED) and one patient died of metastatic
disease at 8 months after resection.15,72 One patient who under-
went cyst fenestration was alive with no recurrence at 14 months
post-procedure (final pathology indicated non-invasive BMCN,
but the patient refused resection), and two of five patients with
partial disease remained alive with recurrent disease.15,72 Of the 18
patients with invasive BMCNs, 13 patients underwent complete
resection and nine underwent longterm follow-up: two remained
alive with NED at 14.4 months and 16 years post-procedure,
respectively; two remained alive with recurrent disease at
4 months and 10 years post-procedure, respectively, and five died
(two with documented metastatic disease).15,72
Reported misdiagnoses
Initial misdiagnosis and the subsequent mistreatment of BMCN
remain persistent. Previous interventions, which are widely vari-
able, have been reported in up to 45% of patients and in some
cases have ultimately resulted in mortality.10,15,72 It is critical to
appreciate these high rates of mismanagement because the goal of
investigation is to decrease the occurrence of misdiagnosis and
mistreatment in the management of BMCN. The literature
includes a report of three patients with preoperative diagnoses of
echinococcal cysts who underwent laparotomies secondary to
misdiagnosis, which resulted in recurrence or incomplete surger-
ies, two of whom were misdiagnosed at surgery for a second time
as having simple cysts.10 A fourth patient was found to have a
suspicious malignant cystic lesion during a cholecystectomy,
which was ultimately diagnosed as an invasive BMCN.10 Finally, a
fifth patient with an initial misdiagnosis of a retroperitoneal
abscess developed multiple right kidney, right rib and right back
metastasis and died 21 months after his initial operation.4
Systemic chemotherapy for recurrence after resection
The value of salvage therapy in patients with recurrent metastatic
invasive BMCNs after complete resection is unclear. It is particu-
larly difficult to evaluate because distant metastasis is seen to
occur very infrequently as local invasion and intrahepatic recur-
rence after excision tend to be the primary modes of malignant
behaviour.4,22 Distant metastases have been reported to occur in
up to 20% of patients and up to 13% have been noted to have
lymphatic spread.2,57 The most common sites of metastasis are the
lungs, pleura, peritoneum, liver, duodenum, stomach and pan-
creas.1,79 In a few patients, osseous metastases have also been
reported.69,79
There is a dearth of literature explicitly reporting the use of
chemotherapy as primary treatment, adjuvant therapy or for
metastatic recurrence after the complete resection of an invasive
BMCN. Lauffer et al. reported three patients in whom chemo-
therapy and/or radiation (as primary treatment) were adminis-
tered without surgery and indicated 2- and 5-year survival rates of
33%.2 No details of the therapy were given. Kasai et al. described
one patient in whom adjuvant chemotherapy (mitomycin,
5-fluorouracil via the hepatic artery) and radiation were provided
and reported survival of 1 year.67 Additionally, at Carolinas
Medical Center one patient with an invasive BMCN previously
treated by resection via a left hepatic trisegmentectomy with en
bloc R0 resection of a stage I cancer (T1N0M0) underwent salvage
chemotherapy (gemcitabine, capecitabine, oxaliplatin) initiated
for recurrent liver tumour and metastatic disease, but died
6 months later. Given that only a handful of cases in which che-
motherapy has been utilized as a primary, adjuvant or salvage
therapy have been reported in the literature, no definitive recom-
mendations in this area can be made.
Prognosis
The prognosis in patients with non-invasive BMCNs is excellent if
complete resection is possible.1 Several case reports have illus-
trated longterm survival following complete, uncomplicated sur-
gical excision; this is considered to reflect the slow growth of these
tumours.10,51,66,80 Thirty of 31 (97%) recently reported patients
with non-invasive BMCN demonstrated significant longterm sur-
vival (up to 11 years).4,6,15,72 The one patient in whom metastatic
disease developed subsequently is likely to have had a cancer focus
in the non-invasive BMCN that was not appreciated on pathology
review.
736 HPB
HPB 2012, 14, 725–740 © 2012 International Hepato-Pancreato-Biliary Association
The prognosis in patients with an invasive adenocarcinoma
arising in conjunction with BMCN (invasive BMCN) is much
harder to predict.1 This is probably multifactorial and secondary
to heterogeneity of management (drainage, fenestration, excision,
ablation) over a long time period in different institutions, and
varying stages and types of tumour (e.g. with and without the
presence of ovarian stroma). Additional data are required to
define more precisely the prognosis in patients with BMCN with
an associated invasive carcinoma using the new definition and
classification.
The natural history of invasive BMCN has been observed in a
few patients followed for 5–22 years via serial imaging studies
which have indicated that the BMCN may take up to 12 years to
become malignant.38,39 Patients who receive an initial correct diag-
nosis and undergo appropriate complete surgical resection would
be expected to achieve the best outcomes. However, this is difficult
to determine as longterm follow-up results for these patients are
often combined with those of patients who have undergone prior
procedures or have non-invasive BMCN. There are some data
available on patients in whom the correct diagnosis was initially
missed or delayed and in whom poorer longterm survival is
reported, but, again, survival rates are frequently combined.4 Sur-
vival data based on the few patients who proceeded to liver trans-
plant suggest outcomes equivalent to those in patients who
undergo transplant for other primary liver tumours.77 The prog-
nosis in recurrent disease with salvage chemotherapy treatment
has been detailed for only a few patients.2,67
Patients with lesions that are confined within the cyst wall may
have a better prognosis than those with tumours that extend
beyond the cystic wall structure.24,26,73 Nakajima et al. performed a
clinicopathologic and histochemical evaluation of nine biliary
cystadenocarcinomas of the liver.26 Tumour growth was com-
pletely confined to the lesion in five patients and extended into the
liver parenchyma or adjacent organs in four patients.26 A marked
difference between the groups in terms of prognosis was noted
(100% survival in patients with confined tumours vs. 0% in
patients with non-confined tumours). Although all the patients
with invasive tumours died in this series, they survived for an
average of 7 months after resection and three remained alive at
1 year post-resection.26
Additionally, other series have suggested that although intrahe-
patic invasive BMCNs are capable of spreading beyond the liver
and metastasizing to distant sites, longterm survival in these
patients, even in those with invasive disease, is improved with
resection.2,8 This lends credence to the supposition that the bio-
logical behaviour of these tumours is widely variable. Too few
patients with intrahepatic invasive BMCN have been reported in
the literature to support a definitive statement regarding the
prognostic value of either tumour invasion or the presence of
distinctive mesenchymal stroma.2
At present, it would appear that patients with invasive adeno-
carcinoma arising in association with BMCN have a better
prognosis than those with pure cholangiocarcinoma, which
emphasizes the importance of distinguishing between disease
types.1 The prognosis of patients with invasive BMCN is better
than that of patients with hepatocellular carcinoma (5-year sur-
vival of 40%) or cholangiocarcinoma (5-year survival of 22%) if
the disease is completely resected.2,10,22,72 This is because primary
biliary invasive MCNs appear to have a less invasive nature and a
slower growth rate than other malignancies of the liver and inva-
sive MCNs of other sites, such as the pancreas or ovaries.22,79
Overall 5-year survival after resection is 65-71% and can reach
100% in patients in whom histologically negative resection
margins are achieved.31,57,79
Conclusions
Preoperative differential workup of a cystic liver tumour should
always include BMCN. Presenting symptoms, laboratory values
and diagnostic imaging features are unreliable and frequently lead
to delayed or incorrect diagnosis and unnecessary procedures that
are likely to have a negative effect on survival. Preoperative cyst
aspiration is not advocated in order to avert the risk for intrap-
eritoneal seeding, but intraoperative cyst wall biopsy and frozen
section(s) are essential to differentiate BMCNs from other cystic
liver tumours. Complete excision of a suspected non-invasive or
invasive BMCN of the liver is clearly the treatment of choice when
the patient is medically fit for surgery and there is no evidence of
systemic disease on initial workup. Survival rates and prognosis
will become more defined as BMCNs are resected with increased
frequency and the appropriate classification is applied.
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